May 2007
Volume 48, Issue 13
ARVO Annual Meeting Abstract  |   May 2007
Treatment of Acute and Chronic Cystoid Macular Edema With Nepafenac 0.1% (NevanacTM)
Author Affiliations & Notes
  • K. Warren
    University of Kansas School of Medicine, Kansas City, Kansas
  • S. M. Hariprasad
    University of Chicago, Chicago, Illinois
  • D. Callanan
    Texas Retina Associates, Dallas, Texas
  • S. Gainey
    Eye Clinic of Manitowoc, Manitowoc, Wisconsin
  • Footnotes
    Commercial Relationships K. Warren, Alcon, Genentech, DORC, C; Alcon, Genentech, DORC, R; S.M. Hariprasad, Alcon, R; D. Callanan, Alcon, R; S. Gainey, Alcon, R.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5465. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. Warren, S. M. Hariprasad, D. Callanan, S. Gainey; Treatment of Acute and Chronic Cystoid Macular Edema With Nepafenac 0.1% (NevanacTM). Invest. Ophthalmol. Vis. Sci. 2007;48(13):5465.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose:: To report on the efficacy of nepafenac 0.1% in the treatment of acute and chronic cystoid macular edema (CME).

Methods:: A retrospective case study evaluating retinal thickness and visual outcomes in patients with either acute or chronic CME.

Results:: We describe six patients with CME who were treated with the NSAID nepafenac 0.1%: Three patients with acute post-operative CME following cataract surgery and three patients with chronic macular edema secondary to uveitis. In the 3 acute cases, a diagnosis of clinical CME was made by clinical exam and OCT. Treatment with three-times-daily topical nepafenac 0.1% was initiated, with or without concomitant steroids. After 3-4 weeks of treatment, improvements in both retinal thickness (mean decrease of 231.7 µm) and visual acuity (mean improvement of 2.0 lines) were observed in all cases. Three eyes with documented chronic CME that had failed previous steroid therapy with or without concomitant NSAIDs, were started on topical nepafenac 0.1% three times daily with or without concurrent steroid treatment. This group demonstrated similar improvements in retinal thickness (mean decrease of 236.7 µm) and visual acuity (mean improvement of 1.8 lines) similar to those with acute CME.

Conclusions:: Treatment with topical nepafenac 0.1% with or without concomitant steroids reduced retinal thickness and improved visual acuity in patients with acute and chronic CME. Nepafanac is a promising drug for the treatment of CME and warrants further investigation of its use in the prevention and treatment of posterior segment inflammation.

Keywords: cataract • inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.